Ravi Rao has joined Sobi (Swedish Orphan Biovitrum AB) as its new head of research and development, replacing Milan Zdravkovic who is leaving the company. Dr Rao joins from Aeglea Biotherapeutics Inc, where he was chief medical officer. He has long-standing experience in early and late stage drug development, as well as in medical affairs for immunology, specialty care and rare diseases. Dr Rao previously worked at GlaxoSmithKline Plc and at Roche Pharmaceuticals and before that, was an academic rheumatologist at Imperial College London, and a post-doctoral fellow at Harvard University in the US.
Sobi announced the appointment on 18 August 2020.
Copyright 2020 Evernow Publishing Ltd.